Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of B/HPIV3/HMPV Vaccines in HPIV3-Seropositive Children
NCT06546423Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Viral Vectors, Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human metapneumovirus infection (HMPV) and human parainfluenza virus type 3 infection comparing B/HPIV3/HMPV-PreF-A vaccine, B/HPIV3/HMPV-F-B365 vaccine and Placebo (3 arms). Primary endpoints: Frequency of Grade 1 or Higher Solicited Adverse Events at 28 days, Frequency of Lower Respiratory Illness at 28 days and 4 more. Started Jul 2024; status: completed.
02
Drugs
B/HPIV3/HMPV-PreF-AB/HPIV3/HMPV-F-B365
03
Conditions
human metapneumovirus infection (HMPV)human parainfluenza virus type 3 infection
Beyond the preview
Go deeper on NCT06546423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06546423.